Market Place
Sourcing Support
Celyad receives approximately EUR 9.8m in private placement from shareholders
24 Aug 2023 //
GLOBENEWSWIRE
Celyad Oncology announces receipt of Nasdaq delisting notice
15 May 2023 //
GLOBENEWSWIRE
Celyad announces receipt of Nasdaq initial notification on ADS bid price
24 Apr 2023 //
GLOBENEWSWIRE
Celyad Oncology announces receipt of Nasdaq notice
04 Apr 2023 //
GLOBENEWSWIRE
Celyad Oncology appoints Georges Rawadi as its new CEO
24 Mar 2023 //
GLOBENEWSWIRE
Cash crunches keep Bioasis and Celyad`s feet to the fire
24 Mar 2023 //
FIERCE BIOTECH
Celyad Oncology reports full year 2022 financial results
23 Mar 2023 //
GLOBENEWSWIRE
Celyad to announce full year 2022 financial results and host conference call
17 Mar 2023 //
GLOBENEWSWIRE
Celyad Oncology announces non-cash impairment
15 Mar 2023 //
GLOBENEWSWIRE
Celyad announces publication of data from its Phase 1 THINK study of CYAD-01
09 Feb 2023 //
GLOBENEWSWIRE
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
03 Feb 2023 //
GLOBENEWSWIRE
Celyad Oncology provides an update on its strategic business model
21 Dec 2022 //
GLOBENEWSWIRE
Celyad Oncology Announces 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Cellistic & Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations
19 Sep 2022 //
GLOBENEWSWIRE
Celyad Oncology Reports First Half 2022 Financial Results
05 Aug 2022 //
GLOBENEWSWIRE
Celyad gets the go-ahead to resume CAR-T trial for colorectal cancer
02 Aug 2022 //
ENDPTS
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
01 Aug 2022 //
GLOBENEWSWIRE
Celyad Oncology to Announce First Half 2022 Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
Celyad Oncology Announces Leadership Updates
23 Jun 2022 //
GLOBENEWSWIRE
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Celyad Oncology Announces First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
FDA quickly follows a voluntary pause for CAR-T 2.0 with a clinical hold
03 Mar 2022 //
ENDPTS
Deaths spur Celyad to pause trial of off-the-shelf CAR-T therapy
01 Mar 2022 //
FIERCEBIOTECH
Celyad Oncology Announces $32.5M Private Placement
03 Dec 2021 //
PRESS RELEASE
Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101
18 Jan 2021 //
PRESS RELEASE
Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1
04 Dec 2020 //
GLOBENEWSWIRE
Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T
04 Nov 2020 //
PRESS RELEASE
Celyad Oncology Establishes At-the-Market Facility
13 Sep 2020 //
GLOBENEWSWIRE
Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101
01 Jun 2020 //
GLOBENEWSWIRE
